vs

Side-by-side financial comparison of CAPITAL CITY BANK GROUP INC (CCBG) and Ginkgo Bioworks Holdings, Inc. (DNA). Click either name above to swap in a different company.

CAPITAL CITY BANK GROUP INC is the larger business by last-quarter revenue ($63.5M vs $33.4M, roughly 1.9× Ginkgo Bioworks Holdings, Inc.). On growth, CAPITAL CITY BANK GROUP INC posted the faster year-over-year revenue change (6.0% vs -23.8%). CAPITAL CITY BANK GROUP INC produced more free cash flow last quarter ($80.0M vs $-47.7M). Over the past eight quarters, CAPITAL CITY BANK GROUP INC's revenue compounded faster (6.0% CAGR vs -6.2%).

Texas Capital Bank is a bank headquartered in Dallas, Texas. The bank has branches located in every major city in Texas. Its parent bank holding company is Texas Capital Bancshares. It also operates an online-only banking division, Bask Bank.

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

CCBG vs DNA — Head-to-Head

Bigger by revenue
CCBG
CCBG
1.9× larger
CCBG
$63.5M
$33.4M
DNA
Growing faster (revenue YoY)
CCBG
CCBG
+29.8% gap
CCBG
6.0%
-23.8%
DNA
More free cash flow
CCBG
CCBG
$127.7M more FCF
CCBG
$80.0M
$-47.7M
DNA
Faster 2-yr revenue CAGR
CCBG
CCBG
Annualised
CCBG
6.0%
-6.2%
DNA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CCBG
CCBG
DNA
DNA
Revenue
$63.5M
$33.4M
Net Profit
$13.7M
Gross Margin
Operating Margin
29.3%
-211.9%
Net Margin
21.6%
Revenue YoY
6.0%
-23.8%
Net Profit YoY
4.7%
EPS (diluted)
$0.80
$-1.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCBG
CCBG
DNA
DNA
Q4 25
$63.5M
$33.4M
Q3 25
$65.9M
$38.8M
Q2 25
$63.2M
$49.6M
Q1 25
$61.5M
$48.3M
Q4 24
$59.9M
$43.8M
Q3 24
$59.7M
$89.0M
Q2 24
$58.9M
$56.2M
Q1 24
$56.5M
$37.9M
Net Profit
CCBG
CCBG
DNA
DNA
Q4 25
$13.7M
Q3 25
$15.9M
$-80.8M
Q2 25
$15.0M
$-60.3M
Q1 25
$16.9M
$-91.0M
Q4 24
$13.1M
Q3 24
$13.1M
$-56.4M
Q2 24
$14.2M
$-217.2M
Q1 24
$12.6M
$-165.9M
Operating Margin
CCBG
CCBG
DNA
DNA
Q4 25
29.3%
-211.9%
Q3 25
32.0%
-231.8%
Q2 25
31.7%
-132.1%
Q1 25
35.8%
-184.1%
Q4 24
29.0%
-236.3%
Q3 24
26.1%
-62.0%
Q2 24
29.3%
-396.7%
Q1 24
27.2%
-469.1%
Net Margin
CCBG
CCBG
DNA
DNA
Q4 25
21.6%
Q3 25
24.2%
-207.9%
Q2 25
23.8%
-121.6%
Q1 25
27.4%
-188.2%
Q4 24
21.9%
Q3 24
22.0%
-63.3%
Q2 24
24.0%
-386.4%
Q1 24
22.2%
-437.3%
EPS (diluted)
CCBG
CCBG
DNA
DNA
Q4 25
$0.80
$-1.41
Q3 25
$0.93
$-1.45
Q2 25
$0.88
$-1.10
Q1 25
$0.99
$-1.68
Q4 24
$0.78
$-1.91
Q3 24
$0.77
$-1.08
Q2 24
$0.83
$-4.23
Q1 24
$0.74
$-3.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCBG
CCBG
DNA
DNA
Cash + ST InvestmentsLiquidity on hand
$422.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$552.9M
$508.6M
Total Assets
$4.4B
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCBG
CCBG
DNA
DNA
Q4 25
$422.6M
Q3 25
$495.5M
Q2 25
$559.4M
Q1 25
$325.3M
Q4 24
$561.6M
Q3 24
$616.2M
Q2 24
$730.4M
Q1 24
$840.4M
Stockholders' Equity
CCBG
CCBG
DNA
DNA
Q4 25
$552.9M
$508.6M
Q3 25
$540.6M
$559.8M
Q2 25
$526.4M
$613.0M
Q1 25
$512.6M
$647.4M
Q4 24
$495.3M
$716.1M
Q3 24
$476.5M
$797.9M
Q2 24
$461.0M
$833.1M
Q1 24
$448.3M
$987.3M
Total Assets
CCBG
CCBG
DNA
DNA
Q4 25
$4.4B
$1.1B
Q3 25
$4.3B
$1.2B
Q2 25
$4.4B
$1.2B
Q1 25
$4.5B
$1.3B
Q4 24
$4.3B
$1.4B
Q3 24
$4.2B
$1.5B
Q2 24
$4.2B
$1.6B
Q1 24
$4.3B
$1.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCBG
CCBG
DNA
DNA
Operating Cash FlowLast quarter
$87.6M
$-47.7M
Free Cash FlowOCF − Capex
$80.0M
$-47.7M
FCF MarginFCF / Revenue
126.1%
-142.8%
Capex IntensityCapex / Revenue
12.0%
0.0%
Cash ConversionOCF / Net Profit
6.39×
TTM Free Cash FlowTrailing 4 quarters
$150.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCBG
CCBG
DNA
DNA
Q4 25
$87.6M
$-47.7M
Q3 25
$21.6M
$-31.6M
Q2 25
$32.6M
$-40.3M
Q1 25
$21.9M
$-51.5M
Q4 24
$63.6M
$-42.4M
Q3 24
$12.8M
$-103.5M
Q2 24
$24.9M
$-84.4M
Q1 24
$14.6M
$-89.3M
Free Cash Flow
CCBG
CCBG
DNA
DNA
Q4 25
$80.0M
$-47.7M
Q3 25
$19.8M
Q2 25
$30.8M
$-40.3M
Q1 25
$19.5M
$-59.1M
Q4 24
$54.9M
$-56.1M
Q3 24
$10.5M
$-118.6M
Q2 24
$23.0M
$-111.4M
Q1 24
$12.4M
$-96.0M
FCF Margin
CCBG
CCBG
DNA
DNA
Q4 25
126.1%
-142.8%
Q3 25
30.1%
Q2 25
48.7%
-81.2%
Q1 25
31.7%
-122.4%
Q4 24
91.7%
-128.0%
Q3 24
17.6%
-133.2%
Q2 24
39.0%
-198.2%
Q1 24
22.0%
-252.9%
Capex Intensity
CCBG
CCBG
DNA
DNA
Q4 25
12.0%
0.0%
Q3 25
2.6%
0.0%
Q2 25
2.9%
0.1%
Q1 25
3.9%
15.8%
Q4 24
14.5%
31.3%
Q3 24
3.8%
16.9%
Q2 24
3.3%
48.1%
Q1 24
4.0%
17.7%
Cash Conversion
CCBG
CCBG
DNA
DNA
Q4 25
6.39×
Q3 25
1.35×
Q2 25
2.17×
Q1 25
1.30×
Q4 24
4.86×
Q3 24
0.97×
Q2 24
1.76×
Q1 24
1.17×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CCBG
CCBG

Segment breakdown not available.

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

Related Comparisons